Identifying urine markers for cancer screening
To Identify Potential New Urine Marker Panel for Cancer Screening
Chinese University of Hong Kong · NCT04689802
This study is testing whether certain substances in urine can help detect different types of cancer in adults more easily and without invasive procedures.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong (other) |
| Locations | 1 site (Shatin) |
| Trial ID | NCT04689802 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the use of urinary polyamines as potential biomarkers for the diagnosis of various cancers. By analyzing urine samples from adult patients with confirmed cancer diagnoses and healthy controls, the study seeks to assess the correlation between urinary polyamine levels and other metabolites. The goal is to establish a non-invasive method for cancer detection and monitoring, which could simplify the screening process for patients.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old with a histological diagnosis of cancer or healthy individuals without a cancer diagnosis.
Not a fit: Patients with recent urinary tract infections or those who have undergone urethral instrumentation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a simple and non-invasive urine test for early cancer detection.
How similar studies have performed: While there have been reports on the use of polyamines in cancer diagnosis, this study represents a larger scale investigation into their effectiveness as biomarkers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult patients with age \> 18 years old. 2. For cancer patients, a histological diagnosis of cancer is available. 3. For normal control, there is no diagnosis of cancer in the medical record. Exclusion Criteria: 1. Patient with recent urinary tract infection within 6 weeks prior to urine collection. 2. Patient with recent urethral instrumentation, such as Foley catheter insertion, cystoscopy etc, within 6 weeks prior to urine collection. 3. Patient refused or unable to provide consent for the study
Where this trial is running
Shatin
- Prince of Wales Hospital — Shatin, Hong Kong (RECRUITING)
Study contacts
- Principal investigator: Chi Fai Ng, MD — Chinese University of Hong Kong
- Study coordinator: Chi Fai Ng, MD
- Email: ngcf@surgery.cuhk.edu.hk
- Phone: 35052625
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer